Sodium Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced Ejection Fraction

This is a recording of Pharmacotherapy Rounds presented by Dr. Andrew Willeford, PGY2 Cardiology Pharmacy Resident, at the University of Maryland.

[@JoseRodriguez-fu7np]

Amazing presentation helped me find the clean summarized points of all these trials!

[@2DElectronGas]

Excellent presentation, thank you!

[@deriarara376]

Thank you so much. Really good presentation

[@andersbarasa3191]

Excellent. Good job.

[@beingamenda2020]

this was such an amazing presentation
Thank you so much!

[@dr.aravindcsa2703]

Great presentation . thank you

[@misstrixie8744]

Great presentation! I wish all conferences presented research this way. Great job

[@CharleyWaters]

Fantastic presentation

[@a7madbisher]

I think you maybe mistaken in slide at min 16
Bcz you said earlier the emperor have sig reduction of cv death but in slide than in min 16 u said it is not significant!!
Anyways it was amazing
Thx alot keep it up

[@beingamenda2020]

He is talking about two different trials! The first one was EMPA-REG and the second one was EMPEROR-reduced!

[@oswaldfernandes8266]

A drug has to be assessed vi's a vi's the covid pandemic. Sglt2 inhibitors cause insulinopenia because of low glucose level therefore low atp which ultimately suppresses the immunity to fight the covid infection. This drug also causes euglycaemic keto acidosis which makes it a dangerous drug despite all its advantage in cardio and renal complication.

[@williampaz4942]

Hello, I would like to point out if a patient has a severe allergy to an ACE/ARB then the benefits of an SGLT-2i are completely unknown. DAPA-HF, DAPA-CKD, EMPEROR-Reduced etc. etc. all had at least 90% of patients on ACEi/ARB etc. therefore, we cannot say any applies to the patient case presented. PATIENTS MUST BE ON STANDARD OF CARE otherwise this is all insufficient to make a determination. Thank you.